1. Home
  2. Products
  3. Customized ADCs
  4. FOLR1
  5. Anti-FOLR1-S-S-Dox ADC

Anti-FOLR1-S-S-Dox ADC (CAT#: ADC-W-602)

This ADC product is comprised of an anti-FOLR1 monoclonal antibody conjugated via a linker to Dox. The Dox is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Dox binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • FOLR1
  • Alternative Names
  • FOLR1; folate receptor 1 (adult); FBP; FOLR; folate receptor alpha; FR-alpha; KB cells FBP; folate binding protein; folate receptor, adult; adult folate-binding protein; ovarian tumor-associated antigen MOv18;
  • Target Entrez Gene ID
  • 2348
  • Overview
  • The protein encoded by this gene is a member of the folate receptor family. Members of this gene family bind folic acid and its reduced derivatives, and transport 5-methyltetrahydrofolate into cells. This gene product is a secreted protein that either anchors to membranes via a glycosyl-phosphatidylinositol linkage or exists in a soluble form. Mutations in this gene have been associated with neurodegeneration due to cerebral folate transport deficiency. Due to the presence of two promoters, multiple transcription start sites, and alternative splicing, multiple transcript variants encoding the same protein have been found for this gene.
  • Overview
  • Anti-FOLR1 Antibody
  • Species Reactivity
  • Human
  • Name
  • disulfide (“S-S”) linker
  • Description
  • Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.
  • Name
  • doxorubicin
  • Description
  • Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-602. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Payload
CAT# Product Name Linker Payload
ADC-W-516 Anti-FOLR1-SPDB-DM4 ADC-5 SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-402 Anti-FOLR1-sulfo-SPDB-DM4 ADC-6 sulfo-SPDB DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1167 Anti-FOLR1 (Farletuzumab)-SPDB-DM4 ADC SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine)
ADC-W-1169 Anti-FOLR1 (Farletuzumab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-1166 Anti-FOLR1 (Farletuzumab)-SMCC-DM1 ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine)
CAT# Product Name Linker Payload
ADC-W-504 Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin
ADC-W-578 Anti-CD74-MCC-Dox ADC MCC (Maleimidomethyl cyclohexane-1-carboxylate) doxorubicin
ADC-W-340 Anti-TNFRSF8-DIBO-doxorubicin ADC-12 DIBO (dibenzylcyclooctynol) doxorubicin
ADC-W-479 Anti-CD74-SMCC-Dox ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin
ADC-W-571 Anti-ERBB2 (Trastuzumab)-DOX ADC thiomaleamicacids-p-aminobenzyloxycarbonyl doxorubicin

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.